Figure 3
PP2A is involved in resistin-induced breast cancer cells invasion.
MDA-MB-231 cells were (A) treated with different doses of resistin and cultured for 1 h, or (B) treated with resistin (25 ng/ml) for the indicated time points. Western blots were conducted on cell lysates (30 μg) and the membrane was probed for phospho-PP2A with PP2A serving as the control. (C) MDA-MB-231 cells were immunoprecipitated with anti-PP2A antibody, followed by western blots against c-Src and PP2A. (D) Cells were treated with 25 ng/ml resistin for the indicated times and cell lysates were immunoprecipitated with anti- PP2A antibody. Western blots were performed to detect protein expression of PP2A and Src. (E) Cells were treated with PP2 (0, 1, 3, 10, or 30 μM). Cell lysates (30 μg) were analyzed by western blots using antibodies against phospho-PP2A and phospho-c-Src, while PP2A and c-Src served as controls. (F) Cells were pre-treated with PP2 (10 μM) and incubated with 25 ng/ml resistin for 60 min. Cell lysates (30 μg) were analyzed by western blot using antibodies against phospho-PP2A and phospho-c-Src, while PP2A and c-Src served as controls. (G) For the Matrigel invasion assay, the number of cells invading through the Matrigel was represented by each column (4 replicates). The results are displayed as mean ± SD from 3 independent experiments. *P < 0.05 vs. untreated condition. **P < 0.05 vs. resistin-treated condition.
